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Abstract 
Statistical Evaluation of the Potency of Test Sample Lots 
Victoria Sandler 
Jason Liao, PhD (Preceptor) 
Zekarias Berhane PhD (Advisor) 
 
Objective: The significance of this project lies in the unique opportunity it affords to test the 
evaluation of test sample lots for the In Vitro Relative Potency (IVRP) of the Human Papilloma 
Virus Types 6,11,16,18 Virus Like Particles.  The problem being addressed by this project is 
how to develop and design statistical procedures for testing potency for the released lot of 
drug/product.  The three questions needed to answer in order to create the best fitted procedure 
are: 1) Minimum possible steps needed to reach the best results, 2) How many results should be 
used to calculate % Relative Standard Deviation (%RSD) at each step (2 or 3)?, and 3) Should all 
samples be used or just the non-deleted ones (without the extremes deleted at each step). 
Methods: The study was based on a simulation data set compiled using SAS® program in a 
sequential sampling manner.  A procedure of calculations was created in order to test the potency 
using the %RSD.  If the %RSD is less than 20% then the test is significant, otherwise it must be 
repeated to reach this %RSD.  The three questions were answered during the study using graphs 
compiled from the simulation data results. There were three sets of graphs generated in this 
study, which were compared to create the new procedure. Set 1: Compares the |Bias| and MSE of 
log-µ and sigma of three, four, and eight steps with seven different levels of CV.  Each level of 
CV has six different values (three for |bias| and three for MSE).  Set 2: Compares using all 
numbers vs. non-deleted numbers of the |Bias| and MSE of log-µ and sigma for each separate CV 
while adding three additional samples or two additional samples.  Set 3: Compares having two 
additional samples vs. three additional samples of the |bias| and MSE for log-µ and sigma for 
each separate CV while using all numbers or non-deleted numbers.    
Results:  Based on the Bias and MSE graphs the main findings were that the procedure should 
include: Three steps, three additional samples should be chosen in each step rather than two, and 
only the non-deleted numbers should be used to calculate the potency.  
Conclusions: The main finding of this study shows that the original procedure should be altered. 
The original procedure stated that all of the numbers should be used, however the findings 
suggest that only the non-deleted numbers should be used to calculate the potency.  In order for 
this study to be applicable some of the data should become contaminated for a better 
representation of real life.  This study was proven to be effective because alterations to the 
procedure will help to calculate the potency for future vaccine lots. 
 
vi 
 
 
 
1 
 
Introduction: 
The significance of this project lies in the unique opportunity it affords to test the 
evaluation of test sample lots for the In Vitro Relative Potency and Completeness of Adsorption 
of the Human Papilloma Virus Types 6,11,16,18 Virus Like Particles.  The test is done using the 
Enzyme-Linked Immunosorbent Assay (ELISA) and must comply with certain criteria for the 
Percent Relative Standard Deviation (%RSD) of the three runs. Creating simulation data in the 
SAS ® program allows to see what the right amount of runs are necessary in order for the 
information to be considered significant.  The problem being addressed by this project is how to 
develop and design statistical procedures for testing and reporting potency for the released lot of 
drug/product.  
Background: 
The Human Papilloma Virus (HPV) is the most common sexually transmitted infection 
(STI) in the United States, with about 6.2 million cases diagnosed annually1. There are more than 
100 strains of HPV, with over 30 types that can cause cervical cancer and genital warts.  HPV is 
an STI that can be transmitted through genital contact without intercourse. Most HPV infections 
are asymptomatic and will typically resolve themselves. Certain strains, however, can have 
serious clinical consequences, including genital warts and cervical cancer. HPV infection is 
associated with the vast majority of cases of cervical cancer. In 2007, there were over 550,000 
new cases of cervical cancer worldwide, and approximately 260,000 deaths from cervical 
cancer1. The overwhelming majority of these women were in the developing countries, where 
cervical cancer screening programs and infrastructures for prevention, diagnoses, and treatment 
are weak2.  It was estimated that 11,000 new cases of invasive cervical cancer and approximately 
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3,700 deaths from cervical cancer occurred in the United States in 20073. This lower rate is 
attributable to the success of the widespread use of the Papanicolaou (Pap) test, which detects 
changes in cervical tissue, and is a major screening tool used for early identification of cervical 
cancer. If detected early, cervical cancer is highly treatable. In the United States, it is 
recommended that women receive Pap tests at least once every three years1. However, many 
women still do not receive Pap tests at the recommended level of frequency. In particular, 
Asian/Pacific Islander women have significantly lower rates of Pap tests than women of other 
races. Cervical cancer incidence and mortality are approximately 1.5 times higher among African 
American and Latina women, compared to White women4. Researchers have postulated several 
reasons for these disparities, including fear, cost, lack of physician referral, and cultural issues5.  
 In June 2006, a new vaccine produced by Merck called Gardasil, which protects against 
certain strains of HPV, was approved by the U.S. Food and Drug Administration (FDA) for use 
in girls and women ages 9 to 26. Following the FDA approval of the Gardasil vaccine, the 
federal Advisory Committee on Immunization Practices (ACIP), a committee of the Centers for 
Disease Control and Prevention (CDC), recommended the new vaccine be administered routinely 
to girls 11 to 12 years of age6.   These recommendations were designed to encourage vaccination 
before initiation of sexual activity, and were based on data from clinical trials demonstrating a 
greater immune response in girls ages 10 to 15 compared to young women ages 16 to 257.   
Gardasil prevents infection of four strains of HPV—two strains (16, 18) that cause 70% of 
cervical cancer cases and two strains (6, 11) that cause 90% of genital warts cases6. It does not 
protect against all types of cervical cancer-causing HPV. Therefore, regular Pap tests remain a 
critical tool for early detection of precancerous cells8. Gardasil should be administered in three 
doses over six months. Presently, there is only enough research to show vaccine effectiveness for 
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5 years. Further research will determine whether booster shots are needed. Furthermore, clinical 
trials were conducted in 9- to 26-year-old females, so effectiveness is only known for this age 
group, not for older women or males6.  
The vaccine production process is a very long process which requires many steps of 
testing before it can be released to the public for use.  The first step to licensing a new vaccine is 
safety testing in animals. If the laboratory animals immunized with the vaccine don't have 
serious reactions, FDA consults with the vaccine manufacturer or sponsor on further refining of 
the manufacturing process9. Only after those studies have been completed, does testing in people 
begin. FDA requires new vaccines to undergo several phases of clinical trials, testing in people, 
for safety and effectiveness.  One of the very first steps in the human testing process is the Phase 
I clinical trial.  During this phase the researchers have to evaluate basic safety and identify only 
very serious or very common adverse events9. These trials are small--between 20 and 100 
patients--and last just several months.  Phase 2 trials include several hundred patients and last 
anywhere from several months to two years9. This allows for more information on safety and 
preliminary information on effectiveness to be collected.  Unless severe reactions or a lack of 
effectiveness surfaces during the first two phases, the trials are expanded in Phase 3 to include 
several hundred to several thousand people9. These trials continue to measure effectiveness and 
safety.  If, towards or at the end of the Phase 3 trials, the manufacturer believes there are 
adequate data to show that the vaccine is safe and effective for its intended use, the manufacturer 
applies to FDA for two licenses--one for the vaccine (product license) and one for the 
manufacturing plant (establishment license)9.  An internal FDA committee then reviews the 
clinical data, proposed labeling, and manufacturing protocols that ensure a consistent product, 
and the results of the agency's own confirmatory tests of the vaccine's components and the final 
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product. The review process includes an inspection of the manufacturing facility. Licensing of a 
vaccine is only the beginning of FDA's oversight. Manufacturers must submit samples of each 
vaccine lot and results of their own tests for potency, safety and purity to the agency before 
release9.  Each lot must be tested because vaccines are derived from living organisms that are 
sensitive to environmental factors and are susceptible to contamination.  The tests manufacturers 
must perform on each lot are spelled out in the Code of Federal Regulations or in the product 
license application9. When the manufacturer sends the lot samples, along with the results of 
testing, to FDA, the FDA either tests the lot sample or goes with the manufacturer's 
documentation.  Over the last 10 years, there have been only three vaccine recalls9. One lot was 
recalled after FDA detected particulates; another was mislabeled. The third lot was recalled 
because of potential problems after an FDA inspection found violations of good manufacturing 
practices at the production plant9. 
When the Gardasil vaccine was being developed, all of these steps were followed in the 
clinical trial process in order for the vaccine to be released.  During the Phase Clinical Trial, the 
objective was to determine the safety and immunogenicity of four dose formulations of 
monovalent HPV 11 L1 VLP vaccine (administered at 0, 2 and 6 months) in women 18-25 years 
of age7.  This was a Phase I, randomized, double-blind, multicenter, sequential dose-escalating 
placebo controlled trial.  All subjects, investigators and their staff, and laboratory personnel were 
blinded to the treatment group.  The study was conducted at 2 centers in the U.S and the subjects 
were healthy females 18-25 years of age, and seronegative for anti-HPV 117.  The subjects could 
not have a history of evidence of HPV related disease7. Subjects had to have a negative 
pregnancy test on the day of vaccination in order to receive study material.  The Subjects then 
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received vaccine formulation or placebo (0.5 mL) at 0, 2, and 6 months by IM injection in the 
deltoid muscle7. 
When assessing the results of this trial it was found that the vaccine was proven to be 
effective in the given population.  None of the women who were enrolled in the study until the 
end tested positive for the tested strains of HPV.  It was also shown that the administration of the 
fourth dose did not produce any meaningful increases in antibody levels after end of study 
compared to the third dose7. Once these results were assessed, the fourth dose was removed from 
the study.  The next trials in Phase I had the same populations except that they were testing for 
the other strains of HPV and now only using three doses instead of four7.  Since all of these 
studies proved to be effective, the study was moved into Phase II and Phase III successfully.     
This project will compare and evaluate different procedures for obtaining the potency for 
the release of vaccine lots.  This is very important because it will allow people to check for 
potency of the lots which are being released for public use.  If the lots are not potent enough then 
the vaccine will not be useful and will not be able to prevent the targeted disease. 
Statistical Procedure: 
Once the vaccine was approved, the lots which have been produced must be tested using 
an immunoassay test called ELISA to make sure that the lots are potent and ready for release.  
Statistical evaluation of the laboratory data must be performed to ensure that the lots are potent 
and can be released for use.  To this end, a statistical procedure was used to release the vaccine 
lot and to report the potency of the released vaccine lot.  The detail of the statistical procedure is 
as follows:  Three independent runs (or 3 plates) of each individual test sample are required to 
generate a reportable potency value for In Vitro Relative Potency (IVRP) samples. Each sample 
6 
 
run (plate) must be performed on separate days, with separate technicians, and/or independent 
preparations of all qualified reagents including the reference standard. Therefore, three plates are 
required per test for IVRP samples using one vial for each independent sample preparation per 
plate.  Once the test is ran in the laboratory the results with the values must be analyzed and 
calculated so that a potency value can be reported for the lots which are being tested.  The test 
plan for calculating the potency values allowing repeated tests for a total of nine test results 
should be performed as follows.  The first step is to test three plates to estimate the Percent 
Relative Standard Deviation (% RSD).  If the % RSD is less than or equal to 20% then stop the 
testing, otherwise proceed to step 2.  The second step is to drop the highest and the lowest, and 
test three more times and calculate the % RSD based on the results of the four plates. If % RSD 
is less than or equal to 20% then stop, otherwise proceed to step 3.  The third step is to drop the 
highest and the lowest, and test three more times and calculate the potency level and report the % 
RSD based on the results of all five plates.  If % RSD fails in step 3, calculate the % RSD using 
all nine plates performed.  If the test fails in the last step then an investigation is needed in order 
to find out why the lots are failing to achieve the desired potency.  This is a sequential sampling 
procedure and it must be done using three separate runs.  The following is an example of the test 
plan step by step.   
Step 1: Let the potency of the first three plates be 50, 58, and 76.  Then %RSD=22%, which is 
greater than 20% thus, then go to step 2. 
Step 2: Drop 50 and 76, and test three more plates. Let these estimates are 49, 76, and 61. Then 
calculate the % RSD based on four numbers 58, 49, 76, and 61. Implies, %RSD=18.63%, which 
is less than 20% and stop here.   
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Based on the samples at hand (maximum 9 samples), a 95% lower confidence bound for 
the true IVRP is derived in the usual way (eq. 1) and in a conservative way by replacing the 
sample mean with the sample median (eq. 2).  Since one needs to be confident that each lot 
satisfies its minimum potency specification, use of the median tends to be conservative since the 
median is not nearly as impacted by large outliers as the mean.  Calculations are done in the 
natural log scale and then converted back at the end.   
 In order to calculate the % RSD we will use the following statistical equations.  
Assuming the results of the nine runs are available and 
x1, x2…., x9 are the IVRP data corresponding to the 9 runs and yj=ln (xj) for j=1, 2, …9. To 
calculate the %RSD, the following steps will be used: 
1. Compute the geometric mean (GM), i.e.: 
 yeGM           
2. Estimate of the median. 
3. Let s be the standard deviation of the ln transformed data, sYi
' . Then: 
)1(100% ˆ  seRSD   
4. For the case where n=9, the lower confidence bound is defined as follows  
3/8,05.0)100/1( tL RSD
GMMean    
Equation 1 
3/8,05.0)100/1( tL RSD
MedianMedian    Equation 2
 
where t0.05,8  is the 95th percentile point from t-distribution with 8 degrees of freedom. 
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Specific Aims: 
In order to create the best fitted procedure for the test the following three questions must 
be answered during the course of the study.  1) How many steps should be used to reach the best 
results, 2) How many additional results should be resampled at each step (2 or 3), and  3) Should 
all of the numbers be used in the calculations or just the non-deleted ones (without the extremes 
deleted at each step)? This is the main focus of the study and the three questions which needed to 
be answered in order to create the best statistical procedure. 
Research Design and Methods: 
To answer the three questions and to tone the described statistical procedure, simulated 
study was performed using the statistical package SAS®.  The current statistical procedure was 
modified to allow different number of steps (3,4,8), different size of samples to add at each step 
(2 or 3), and different sets of cumulative samples (all sampled results vs. only the non-deleted 
ones) used at end for final calculation of the potency of %RSD.  Thus, a total of 12 different 
scenarios (i.e. statistical procedures) were compared.  To obtain a more general picture, seven 
different levels of CV’s (10%, 15%, 19%, 20%, 21%, 25%, 35%) were used in simulating the 
data set.  Each simulation setting from a log-normal distribution was repeated 1000 times.  The 
absolute bias, (i.e. |estimate minus true value|) and mean squared error (MSE) for the mean and 
variance were used as procedure selection criteria.  All of the data was generated randomly and 
the output includes estimates of the |bias| and MSE, was given in tables which were then used to 
create graphs using Excel.  Many graphs were created in order to make a comparison of the |bias| 
and MSE between the different procedures so that the three main questions could be answered.  
That is, each graph created compares the |bias| and MSE from the different approaches 
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(procedures) so that an evaluation could be made on which was the best procedure for this study.  
There were three sets of graphs generated in this study, which were compared to create the new 
procedure. 
 Set 1: Compares the |Bias| and MSE of log-µ and sigma of three, four, and eight steps 
with seven different levels of CV’s (10%, 15%, 19%, 20%, 21%, 25%, 35%). Each level 
of CV has six different values (three for |bias| and three for MSE). 
 Set 2: Compares using all numbers vs. non-deleted numbers of the |Bias| and MSE of log-
µ and sigma for each separate CV while adding three additional samples or two 
additional samples.   
 Set 3: Compares having two additional samples vs. three additional samples of the |bias| 
and MSE for log-µ and sigma for each separate CV while using all numbers or non-
deleted numbers.    
Each of these graphs represents a different possible procedure for calculating the potency. 
Results: 
 In order to answer the first question, that is how many steps should be used; The MSE 
and |Bias| of all of the steps in estimating log (µ) and sigma were computed and these were 
plotted to compare the MSE and |Bias| of all of the steps.  A graph was made for both the log (μ) 
and sigma results using all of the samples as well as those based on the samples without the 
deleted plates. These results are shown in Figure 1 for log (µ) and Figure 2 for σ, respectively 
when all of the numbers were used.  The results for the non-deleted numbers only also showed 
similar results (not shown here).   
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Figure1: Comparison of |Bias| and MSE for Log (μ) for the procedure of using three, four, 
and eight steps with different CVs using all of the numbers to calculate potency. 
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Figure 2: Comparison of |Bias| and MSE for Sigma for the procedure of using three, four, 
and eight steps with different CVs using all of the numbers to calculate potency. 
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Figure 3: Comparison of |Bias| and MSE for log-ૄ for the procedure of using three, four, 
and eight steps with different CVs using the non-deleted numbers to calculate potency. 
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CV with using three, four, and eight steps.  The results on this graph also show that using three 
steps is a better approach then using four or eight steps.  The MSE for three steps is lower than 
for four and eight steps.  Thus, using three steps is chosen as an appropriate and cost-efficient 
method to give a reasonable result because this is where the |bias| and MSE are the most stable.   
The second question which had to be answered during the study was how many 
additional samples should be chosen after deleting the highest and lowest values, two or three. 
The original procedure states that three samples should be chosen, but two were also tested in 
order to see what the best results would be.  Figure 4, 5, and 6 show the relationship between 
using three additional samples for each run in the assay test as opposed to using only two 
additional samples in the assay test.  Each figure is also showing the results for each of the three 
different groups possible, using three steps, four steps, or eight steps in the procedure.   
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Figure 4: Plot of |Bias| of log-ૄ for the procedure that use two vs. three additional samples 
at each step for non-deleted numbers only.  
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Figure 5: Plot of |Bias| of Sigma for the procedure that use two samples vs. three additional 
samples at each step for non-deleted numbers only. 
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Figure 6: Plot of MSE of Sigma for the procedure that use two samples vs. three additional 
samples at each step for non-deleted numbers only. 
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numbers, and it also shows the same result as the other two previous figures which is, to use 
three samples instead of two before deleting the high and low.  Even though each figure is 
showing the results for different parameters, the same conclusion can still be made.  In this case, 
it does not matter what parameters you are looking at, choosing three samples as opposed to two 
is better for the end fitted procedure.  These Figures show that using three samples during each 
run will be better than using two samples for each run because it allows for a bigger chance of 
getting the 20% for the coefficient of variation.   
The final question which was answered during this study was if all of the numbers had to 
be used in the calculations or just the non-deleted numbers.  In the current procedure, all of the 
numbers from each run were used in the calculation of the coefficient of variation.  In the given 
procedure, three steps were used with 3 numbers used for each step, therefore having a total of 
nine numbers to calculate the coefficient of variation.  However, another way of doing the 
procedure was to only use the non-deleted numbers of each step.  For instance, in the three step 
calculation only five numbers would used instead of the original nine.  This was a test to see 
which way would give a better result in terms of |bias| and MSE.  In order to reach a conclusion 
on this issue, graphs were created to compare the |bias| and MSE of using all of the numbers 
versus that of not using all of the numbers for both log (µ) and σ.   
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Figure 7: Plot of |Bias| of log-μ of the procedure that uses all samples vs. non-deleted 
samples with the results of 3 additional samples added at each step. 
 
 
As Figure 7 shows, when looking at the |bias| of the log (μ), it is better to use all of the numbers 
as stated in the original procedure, since the points all lie above the identity line which signifies 
that they should be using all of the numbers for the calculation of the potency. 
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Figure 8: Plot of MSE of sigma for the procedure that uses all samples vs. non-deleted 
samples with the results of 3 additional samples added at each step. 
 
 
Contrary, Figure 8 shows that when looking at the MSE of sigma estimations based on all 
numbers vs. non-deleted, the later approach resulted with relatively smaller MSE.  That is, the 
points lie below the line which signifies that only the non-deleted numbers should be used to 
reach relatively better results.  It should be noted that this is not what has been used in the current 
procedure, where all numbers are used for calculating the variance.  This is a new variation of 
the procedure which should be looked at and modified for the new procedure of testing potency. 
 This portion of the procedure can best be seen by using an example with real calculations.  
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values and continue calculating the %RSD after adding three more results: 36, 40, 41 and 38.  
When calculating the %RSD for these four numbers the result is 11%, since this is less than 
20%, then stop the procedure.  However, to show the difference in the new part of the procedure, 
the mean must be calculated for all of the six numbers and just the four (non-deleted) numbers.  
The mean for all of the numbers is 37.9 and the total %RSD is 16.2%, the mean for the non-
deleted numbers is 35.5 and the %RSD is 11%.  Therefore, when looking at this comparison, the 
mean for all of the numbers would be reported and the %RSD for the non-deleted numbers 
would be reported.  This comparison made in this example can be seen in Table 1, below. 
Table 1: Example of what should be reported using the current procedure and the new 
proposed procedure. 
 All Data 
(Current 
Procedure) 
Non -Deleted 
Data 
(Proposed 
Procedure) 
Mean 37.9 35.5 
RSD 16.2% 11.0% 
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Discussion: 
 The main focus of this study was to find a best fitted statistical procedure for the 
calculation of the results of the laboratory data so that the final potency of the vaccine lots is 
valid for releasing.  The simulation study indicates that the best fitted procedure would include 
using only three steps in the process, as the original procedure had suggested, i.e. three additional 
samples after deleting the highest and lowest values at each step should be used in the procedure. 
Also all of the numbers should be used to report the potency but only the non-deleted numbers 
should be used to perform the calculation for the variance instead of all of the numbers as 
suggested by the original.  The original procedure recommended using only three steps to run 
each assay, but it was thought that using more steps would increase the ability to reduce the bias 
and increase the accuracy.  However based on the simulation data this was not necessarily true.  
This seems to be counterintuitive but these are the results reached from the data analysis.  In a 
simulation setting, the data was constructed to be as ideal as possible without any contamination 
of the population, meaning that there were no outliers and the data fit into the population.  In a 
real life situation, there would be possible outliers and the data may be contaminated.  Further 
simulation study maybe conducted using contaminated data to evaluate the recommended 
procedure.  Log-normal distribution was assumed in simulating the data.  The recommended 
procedure can be evaluated to see how sensitive to the log-normal distribution using other 
distributions.   
 Even though this study was a simulation, it needs to be translated into real life practices.  
These assays are performed in the laboratory in order to see the potency of the vaccine lots 
which need to be released for use.  This test is very important because these vaccines must have 
the right potency in order for them to work for the health of the public.  The statistical procedure 
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used for the calculation must be accurate and efficient so that the drug company can release as 
many vaccines as possible.  If more steps were to be used in the assay test, then this could 
possibly not be cost and time effective for the drug company, therefore the three steps is the best 
result also from the business aspect of the study.  These calculations also have to be precise 
because vaccines are a major help to the health of the public and if they are not potent then they 
have no use.  Vaccines are made to prevent diseases and if these vaccines are not potent then 
they will not be effective and it would cause problems not only for the public but also for the dug 
company.  Therefore, this study is very pertinent to all vaccination studies because the potency 
must be tested for all types of vaccines which are released for public use. 
Conclusions and Recommendations: 
 This study was helpful in determining the best statistical procedure needed for 
determining the potency of the vaccine lots.  It was determined that the procedure should include 
using only three steps in the process, as the original procedure had suggested, three additional 
samples after deleting the high and low should be used in the procedure, and all of the numbers 
should be used to report the potency but only the non-deleted numbers should be used to perform 
the calculation for the variance instead of all of the numbers as suggested by the original.  This 
study is important because it designed the best method of calculation for the release of vaccines 
into the public.  The study had a good design in the simulation portion and all of the data was 
collected in an organized manner.  The plots which were created using the data provided an 
easier method for the comparison of all of the data that was created.  In a real life setting, not all 
of the variations would be possible because it would not be cost and time effective, therefore the 
simulation setting was the best method to use.  This type of study should be conducted in order 
to decide the best method for doing calculations for different procedures in the laboratory 
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necessary for drug production.  The potency value is an extremely important part of the vaccine 
production procedure and it must be determined in order for the vaccine to move into mass 
production.  The lab has to perform many tests but statistical input is needed to design a good 
experiment.  Good statistical inputs will result in good drug products.   
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